Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL890563 | 0.87 | PIK3CD (0.58) | PIK3CD | |
| SCHEMBL975059 | 0.86 | PIK3CD (0.54) | PIK3CDHTT | |
| SCHEMBL17718341 | 0.86 | PIK3CD (0.48) | PIK3CDHTT | |
| SCHEMBL890580 | 0.85 | PIK3CD (0.59) | PIK3CDHTT | |
| SCHEMBL18542826 | 0.82 | HTT (0.51) | PIK3CDHTT | |
| SCHEMBL890522 | 0.82 | PIK3CD (0.56) | PIK3CDHTT | |
| SCHEMBL15744208 | 0.81 | PIK3CD (0.52) | PIK3CDHTT | |
| SCHEMBL16417964 | 0.80 | HTT (0.49) | PIK3CDHTT | |
| SCHEMBL973303 | 0.77 | PIK3CG (0.56) | PIK3CD | |
| SCHEMBL16585327 | 0.75 | PIK3CD (0.45) | PIK3CDHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210253601-A1 | PYRIMIDINONES AS PI3K INHIBITORS | INCYTE HOLDINGS CORPORATION | 2021-08-19 | — | — | US | disclosed |
| US-10829502-B2 | Pyrimidinones as PI3K inhibitors | INCYTE CORPORATION (US) | 2020-11-10 | — | — | US | disclosed |
| US-20200123176-A1 | PYRIMIDINONES AS PI3K INHIBITORS | INCYTE CORPORATION | 2020-04-23 | — | — | US | disclosed |
| US-10428087-B2 | Pyrimidinones as PI3K inhibitors | INCYTE CORPORATION (US) | 2019-10-01 | — | — | US | disclosed |
| US-9975907-B2 | Pyrimidinones as PI3K inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2018-05-22 | — | — | US | disclosed |
| US-20170050987-A1 | PYRIMIDINONES AS PI3K INHIBITORS | INCYTE CORPORATION | 2017-02-23 | — | — | US | disclosed |
| WO-2015042497-A2 | SUBSTITUTED AMINOPYRIMIDINE COMPOUNDS AND METHODS OF USE | CALITOR SCIENCES, LLC (US) | 2015-03-26 | — | — | WO | disclosed |
| US-8940752-B2 | Pyrimidinones as PI3K inhibitors | INCYTE CORPORATION (US) | 2015-01-27 | — | — | US | disclosed |
| US-8754089-B2 | Heterocyclic compounds and their uses | AMGEN INC. (US) | 2014-06-17 | — | — | US | disclosed |
| US-8754089-B2 | Heterocyclic compounds and their uses | AMGEN INC. (US) | 2014-06-17 | — | — | US | disclosed |
| US-8754089-B2 | Heterocyclic compounds and their uses | AMGEN INC. (US) | 2014-06-17 | — | — | US | disclosed |
| EP-2445898-A2 | 4H-PYRIDO[1,2-A]PYRIMIDIN-4-ONE DERIVATIVES AS PI3K INHIBITORS | Amgen, Inc (US) | 2012-05-02 | — | — | EP | disclosed |
| US-20120083502-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2012-04-05 | — | — | US | disclosed |
| US-20120083502-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2012-04-05 | — | — | US | disclosed |
| US-20120083502-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2012-04-05 | — | — | US | disclosed |
| WO-2010151735-A2 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2010-12-29 | — | — | WO | disclosed |
| WO-2010151735-A2 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2010-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10428087-B2 | Pyrimidinones as PI3K inhibitors | PIK3CA, PIK3CD, PIK3CB | PIK3CD 2/4885HTT 3196/4885 |
| US-20210253601-A1 | PYRIMIDINONES AS PI3K INHIBITORS | PIK3CA, PIK3CD, PIK3CB | PIK3CD 2/4885HTT 3196/4885 |
| US-10829502-B2 | Pyrimidinones as PI3K inhibitors | PIK3CA, PIK3CD, PIK3CB | PIK3CD 2/4885HTT 3196/4885 |
| US-20170050987-A1 | PYRIMIDINONES AS PI3K INHIBITORS | PIK3CA, PIK3CD, PIK3CB | PIK3CD 2/4885HTT 3196/4885 |
| US-20200123176-A1 | PYRIMIDINONES AS PI3K INHIBITORS | PIK3CA, PIK3CD, PIK3CB | PIK3CD 2/4885HTT 3196/4885 |
| US-20120083502-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | MCL1, MALT1, BCL9 | PIK3CD 24/4885HTT 1044/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.